• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Immunol . Improved Durability to SARS-CoV-2 Vaccine Immunity following Coimmunization with Molecular Adjuvant Adenosine Deaminase-1

tetano

Editor, Senior Moderator
J Immunol


. 2022 Jun 24;ji2200056.
doi: 10.4049/jimmunol.2200056. Online ahead of print.
Improved Durability to SARS-CoV-2 Vaccine Immunity following Coimmunization with Molecular Adjuvant Adenosine Deaminase-1


Gina M Cusimano[SUP] 1 2 [/SUP], Ebony N Gary[SUP] 3 [/SUP], Matthew R Bell[SUP] 1 2 [/SUP], Bryce M Warner[SUP] 4 [/SUP], Jennifer Connors[SUP] 1 2 [/SUP], Nicholas J Tursi[SUP] 3 [/SUP], Ali R Ali[SUP] 3 [/SUP], Shiyu Zhang[SUP] 5 [/SUP], Gabriela Canziani[SUP] 5 [/SUP], Bhavani Taramangalam[SUP] 1 [/SUP], Emma A Gordon[SUP] 2 [/SUP], Irwin M Chaiken[SUP] 5 [/SUP], Sarah K Wootton[SUP] 6 [/SUP], Trevor Smith[SUP] 7 [/SUP], Stephanie Ramos[SUP] 7 [/SUP], Darwyn Kobasa[SUP] 4 8 [/SUP], David B Weiner[SUP] 3 [/SUP], Michele A Kutzler[SUP] 9 2 [/SUP], Elias K Haddad[SUP] 9 2 [/SUP]



Affiliations

Abstract

Although severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines have demonstrated strong immunogenicity and protection against severe disease, concerns about the duration and breadth of these responses remain. In this study, we show that codelivery of plasmid-encoded adenosine deaminase-1 (pADA) with SARS-CoV-2 spike glycoprotein DNA enhances immune memory and durability in vivo. Coimmunized mice displayed increased spike-specific IgG of higher affinity and neutralizing capacity as compared with plasmid-encoded spike-only-immunized animals. Importantly, pADA significantly improved the longevity of these enhanced responses in vivo. This coincided with durable increases in frequencies of plasmablasts, receptor-binding domain-specific memory B cells, and SARS-CoV-2-specific T follicular helper cells. Increased spike-specific T cell polyfunctionality was also observed. Notably, animals coimmunized with pADA had significantly reduced viral loads compared with their nonadjuvanted counterparts in a SARS-CoV-2 infection model. These data suggest that pADA enhances immune memory and durability and supports further translational studies.
 
Back
Top Bottom